touchCARDIO spoke to Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022, providing the results of the APOLLO trial, a placebo-controlled double-blind dose-ranging trial assessing the magnitude and duration of effects of a short-interfering RNA targeting lipoprotein(a).
Questions
1. Could you give us a brief overview of short interfering ribonucleic acid therapeutics and their clinical potential? 00:12-00:50
2. What are the unmet needs in cardiovascular risk reduction in people with high levels of lipoprotein(a)? 00:50-01:41
3. What are the aims and design of the APOLLO study? 01:41-02:33
4. What have been the findings of the study to date? 02:33-04:58
5. What will be the next steps in the clinical development of SLN360? 04:58-05:48
Speaker Disclosure: Steven Nissen reports that the Cleveland Clinic Center for Clinical Research has received funding to perform clinical trials from Abbvie, AstraZeneca, Amgen, Bristol Myers Squibb, Cerenis, Eli Lilly, Esperion, Medtronic, MyoKardia, Novartis, Pfizer, The Medicines Company, Silence Therapeutics, Takeda and Orexigen. Steven Nissen is involved in these clinical trials, but receives no personal remuneration for his participation. Steven Nissen consults for many pharmaceutical companies, but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
